Literature DB >> 15681760

Current issues in the treatment of human diseases by mucosal tolerance.

Howard L Weiner1.   

Abstract

Tolerance has been defined as a lack of response to self but a more appropriate definition of tolerance is "any mechanism by which a potentially injurious immune response is prevented, suppressed, or shifted to a non-injurious class of immune response." Thus, tolerance is related to productive self-recognition, rather than blindness of the immune system to its auto-components. Oral tolerance, in this sense, is of unique immunologic importance, as it is a continuous natural immunologic event driven by exogenous antigen. Because of their privileged access to the internal milieu, antigens that are continuously in contact with the mucosa are a frontier between foreign and self-components. Thus, oral tolerance is an immunological mechanism that evolved to treat external agents that gain access to the body via a natural route as internal components that then become part of self. Given this, it would seem logical that autoimmune diseases caused by an inappropriate response to self-antigens might ultimately be treated by presenting such autoantigens to the mucosal surface where they can be dealt with in a non-injurious (noninflammatory) immunologic environment. Furthermore, mucosal tolerance as a treatment for autoimmune diseases is an attractive concept, as antigen-specific therapy is the most physiologic means to manipulate immune responses, and mucosal antigen is nontoxic and can be given on a chronic basis. The efficacy of mucosal tolerance has been clearly demonstrated in several animal models.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15681760     DOI: 10.1196/annals.1309.053

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  15 in total

1.  Oral administration of Alequel, a mixture of autologous colon-extracted proteins for the treatment of Crohn's disease.

Authors:  Eran Israeli; Yaron Ilan
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

2.  Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses.

Authors:  Jessica Strid; Robin Callard; Stephan Strobel
Journal:  Immunology       Date:  2006-06-08       Impact factor: 7.397

3.  Induction of antigen-specific tolerance by oral administration of Lactococcus lactis delivered immunodominant DQ8-restricted gliadin peptide in sensitized nonobese diabetic Abo Dq8 transgenic mice.

Authors:  Inge L Huibregtse; Eric V Marietta; Shadi Rashtak; Frits Koning; Pieter Rottiers; Chella S David; Sander J H van Deventer; Joseph A Murray
Journal:  J Immunol       Date:  2009-07-27       Impact factor: 5.422

4.  Myeloperoxidase Peptide-Based Nasal Tolerance in Experimental ANCA-Associated GN.

Authors:  Poh-Yi Gan; Diana S Y Tan; Joshua D Ooi; Maliha A Alikhan; A Richard Kitching; Stephen R Holdsworth
Journal:  J Am Soc Nephrol       Date:  2015-06-05       Impact factor: 10.121

Review 5.  The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment.

Authors:  Andrew P Robinson; Christopher T Harp; Avertano Noronha; Stephen D Miller
Journal:  Handb Clin Neurol       Date:  2014

6.  Mucosal tolerance induced by an immunodominant peptide from rat alpha3(IV)NC1 in established experimental autoimmune glomerulonephritis.

Authors:  John Reynolds; Danielle S Abbott; Julieta Karegli; David J Evans; Charles D Pusey
Journal:  Am J Pathol       Date:  2009-04-30       Impact factor: 4.307

Review 7.  Prospects for antigen-specific tolerance based therapies for the treatment of multiple sclerosis.

Authors:  Danielle M Turley; Stephen D Miller
Journal:  Results Probl Cell Differ       Date:  2010

Review 8.  Mechanism of oral tolerance induction to therapeutic proteins.

Authors:  Xiaomei Wang; Alexandra Sherman; Gongxian Liao; Kam W Leong; Henry Daniell; Cox Terhorst; Roland W Herzog
Journal:  Adv Drug Deliv Rev       Date:  2012-11-02       Impact factor: 15.470

9.  Systemic effects of oral tolerance on inflammation: mobilization of lymphocytes and bone marrow eosinopoiesis.

Authors:  Claudiney M Rodrigues; Olindo A Martins-Filho; Nelson M Vaz; Cláudia R Carvalho
Journal:  Immunology       Date:  2006-04       Impact factor: 7.397

10.  IL-28 supplants requirement for T(reg) cells in protein sigma1-mediated protection against murine experimental autoimmune encephalomyelitis (EAE).

Authors:  Agnieszka Rynda; Massimo Maddaloni; Javier Ochoa-Repáraz; Gayle Callis; David W Pascual
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.